Autoimmune Diseases Diagnosis
Autoimmune Diseases Diagnosis
Diagnosis in autoimmune disease is made by combination, and every part of that sentence is load-bearing. The antibody establishes that the immune system has lost tolerance to something, but it occurs in healthy people and its level does not measure how active the disease is. The clinical picture establishes what is happening to the person. Imaging and, where it would change management, tissue establish the structural and histological position. No single one of them is enough, and the commonest error in either direction comes from treating one of them as though it were.
What an antibody result does and does not tell you
An autoantibody says one thing: the immune system has stopped treating a component of the body's own tissue as self. That is genuinely useful, and it is the whole of what it says unaided. It does not establish that a disease is present, name which one, or measure how active anything is.
Three properties of these antibodies explain why. They occur in people with no autoimmune disease, and the likelihood of finding one rises with age, so a positive result in an older person with no symptoms is close to uninformative. They can precede symptoms by years, which means a positive result today is a statement about the immune system rather than about the person's health today. And they respond slowly, if at all, to treatment that is working, which is why they are not what treatment is adjusted against.
| Element of the result | What it contributes |
|---|---|
| Which antibody was tested | Different antibodies cluster with different conditions, so the choice of test should follow the history rather than a standard panel |
| The pattern, where one is reported | Some patterns point more specifically towards particular conditions than the bare fact of positivity does |
| The titre, and the laboratory's reference range | A low titre at the laboratory's own cut-off and a high one are not the same finding, and they are interpreted differently |
| Which assay and which laboratory | Methods differ, so the same sample can be reported differently; a rising or falling titre is only meaningful on the same assay |
| Why the test was requested | An antibody drawn to investigate a specific picture is informative; one drawn as a screen usually produces a result that is hard to act on |
The practical consequence is worth insisting on: ask for the pattern, the titre and the reference range, and for the same laboratory when the test is repeated. A referral letter recording only “positive” has discarded most of what the test produced, and the person carrying it usually has to have it done again.
ESR and CRP — measuring activity, not the disease
The erythrocyte sedimentation rate and C-reactive protein are the two measurements that track inflammation as it happens, and they are the closest thing this field has to a thermometer. They rise when inflammation is active and fall when it is controlled, which makes them useful in two places: judging whether something is happening now, and judging whether treatment has changed it.
What they are not is a diagnosis. Both are raised by infection, by injury, by surgery, by malignancy and by a great deal else, and both can be normal in someone with active autoimmune disease. An elevated result in someone with no symptoms is a reason to look rather than a reason to treat; a normal result in someone with a swollen joint does not exclude anything.
Two cautions about using them well. They move slowly enough that a reading taken immediately after a change in treatment tells you about the change rather than the result of it, so the interval matters. And they are moved by things unrelated to the disease — anaemia raises the sedimentation rate, and age and intercurrent infection move both — which is why they are read as a trend alongside the examination rather than as a verdict. What complements them is the set of tests describing the organ at risk.
Measuring the organ, not the immune system
Once the mechanism is suspected, the question that decides management is not “how much autoimmunity is there” but “what is it doing to the organ it has landed on”. That question is answered by tests chosen for the organ rather than for the immune system, and the result that matters most is usually the first one, because it is the baseline every later result is compared against.
| Organ at risk | What measures it | What the result decides |
|---|---|---|
| Kidneys | Kidney function on blood, and examination of the urine for protein and blood — ideally a quantified sample rather than a dipstick | Whether the kidney is involved at all, and how much. The single most important baseline in the systemic conditions, and the one most often omitted |
| Blood | A full blood count with a differential | Whether the process involves the blood, and the baseline that later monitoring on treatment depends on |
| Liver | Liver function tests | Whether the liver is involved, and the baseline before medicines that can affect it are started |
| Thyroid | Thyroid-stimulating hormone and free thyroxine, read as a pair, with thyroid antibodies | Whether the gland is failing or overproducing, and whether autoimmunity is the background. Covered in full in the thyroid disorders guide |
| Joints | Examination, with imaging where the findings or the duration warrant it | Whether there is inflammation now, and whether there is damage already — two findings that lead in different directions |
| Lungs and heart | Imaging and lung function where the condition or the symptoms point there | Whether an organ that changes management is involved, before it produces symptoms of its own |
The habit worth forming is to ask what was measured before treatment began. Someone who starts immunosuppressing treatment with no recorded kidney function, no blood count and no acute-phase marker cannot be monitored afterwards, because there is nothing to compare against. Two items on the list are safety tests rather than diagnostic ones — the infection screen and the vaccination review that precede immunosuppression, covered on the treatment page.
Where imaging and tissue change the answer
Imaging and biopsy are not the next rung on a ladder; they are used when the result would change what is done — a fair thing to ask about. Imaging answers a structural question blood cannot: is there inflammation now, fluid, scarring, and how much. Where the joint is involved, imaging separates active inflammation from damage already done, which is what decides whether treatment is escalated or the joint is managed as it now is.
Tissue answers a different and narrower question: what is happening in the tissue itself. In kidney involvement it is often the only thing that separates two conditions that produce identical blood results and quite different treatment requirements, and the detail on the sample — which structures are involved, how much is active and how much is scarred — carries information nothing else provides. In skin, in the salivary gland and in some other sites the same logic applies.
The caution is real rather than decorative. A sample has risks, justified by the decision it informs rather than by the desire to be certain. Where a condition has already been named and the picture is typical, treatment can usually begin without one.
How the pieces are read together
The assessment works because each part constrains the others. An antibody that fits a condition is given weight by a clinical picture that fits the same condition, and is given much less weight without one. Acute-phase markers say whether something is happening now. Organ tests say what it is doing. Imaging and tissue say what it has done and what is still active.
Three combinations recur, and each has a different answer. A positive antibody with a matching clinical picture and abnormal organ tests is a diagnosis being made, and treatment follows. A positive antibody with nothing else abnormal is a note in the record, a documented baseline, and a review point — not a prescription. And a convincing clinical picture with negative antibodies is not a closed question: either the condition is one of the seronegative forms, or the antibody has not appeared yet, and the assessment continues on the picture and the imaging.
The part most often skipped is the explicit statement of what was considered and set aside. A good assessment note names the alternatives — infection, a medicine, thyroid disease, malignancy — and says why each is not the answer; without it, the next clinician starts again. It is also worth asking for the record in writing, with dates and reference ranges, because a result without them is close to useless to whoever reads it next.
When the diagnosis takes time, and what happens meanwhile
Some of these diagnoses are made in one visit. More are made over months, and the reason is usually not that testing is slow but that the conditions declare themselves over time. A single normal examination does not close the question, and neither does a single negative antibody — both describe a moment rather than a course.
What should happen during that interval is not nothing. Three things, specifically. Symptoms are treated rather than left, because joint pain, rash and fatigue have management regardless of whether the name has been settled. The organ at risk is measured and a baseline is recorded, so that a later change is interpretable when it comes. And a review point is set with a date attached, rather than a promise to keep an eye on it — a date is what makes the difference between monitoring and drifting.
A fourth thing is worth naming because it is the one people find hardest: not starting immunosuppressing treatment before the picture justifies it. The instinct to do something is reasonable, but the medicines carry real risks, so the threshold is a diagnosis rather than a suspicion. Where a specific organ has taken the lead, its own guide carries the detail: lupus nephritis and IgA nephropathy at the kidney, thyroid disorders at the gland.